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Abstract
Background: Treatment of chronic myeloid leukemia with a tyrosine kinase inhibitor (TKI) offers significant
improvements over previous treatments in terms of survival and toxicity yet nevertheless is associated with reduced
health-related quality of life and very high cost. Several small studies from Europe and Australia suggested that
discontinuing TKIs with regular monitoring was safe.
Methods: The Life After Stopping TKIs (LAST) study is a large, U.S.-based study that aims to improve the evidence
for clinical decision making regarding TKI discontinuation with monitoring in patients with chronic myeloid
leukemia who have a deep molecular response to TKI therapy. The LAST study is a non-randomized, prospective,
single-group longitudinal study of 173 patients. The co-primary objectives are to determine the proportion of
patients who develop molecular recurrence (> 0.1% BCR-ABLIS) after discontinuing one of four TKIs (imatinib,
dasatinib, nilotinib, or bosutinib) and to compare the patient-reported health status of patients before and after
stopping TKIs. Outcomes are assessed at baseline and throughout the 36-month study follow-up period with a
central laboratory used for blood samples. All samples with undetectable BCR-ABL are also examined using digital
polymerase chain reaction, which is a more sensitive nanofluidic polymerase chain reaction system.
Discussion: Because of their high cost and side effects, discontinuation of TKIs for patients with chronic myeloid
leukemia who have a deep molecular response to TKI therapy is a promising approach to treatment. The LAST
study is the largest U.S.-based TKI discontinuation study. It is the first to allow participation from patients on any of
4 first- and second-generation TKIs, includes a robust approach to measurement of clinical and patient-reported
outcomes, and is using digital polymerase chain reaction to explore better prediction of safe discontinuation.
Trial registration: This study was registered prospectively on October 21, 2014 and assigned trial number
NCT02269267.
Keywords: Chronic myeloid leukemia, Oncology, Targeted therapy, Tyrosine kinase inhibitor, Discontinuation,
Clinical trial, Study design, Patient-reported outcome
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Background
Tyrosine kinase inhibitors (TKIs) have dramatically
improved the survival of patients with chronic mye-
loid leukemia (CML), leading to an unforeseen in-
crease in prevalence. Prevalence in 2010 was
estimated at more than 70,000 patients in the U.S.
and is projected to rise to 180,000 by 2050 [1].
Current guidelines recommend continuation of TKI
therapy indefinitely [2] (www.nccn.org). TKIs offer a
significant improvement over previous CML treatments in
terms of survival and toxicity [3, 4], yet nevertheless are
associated with reduced health status, including fatigue,
nausea, depression, sleep disturbances, diarrhea, pain,
fluid retention, and skin problems [5], especially as com-
pared to peers without cancer [6]. With only 15 years of
follow up, the very long-term side effects of TKIs remain
unknown [7]. Of note, some deleterious side effects have
been recognized with longer follow-up, for example,
pulmonary hypertension in patients on dasatinib [8] and
peripheral arterial occlusive disease in patients on
nilotinib [9]. Finally, TKI therapies are among the most
expensive, costing $92,000–138,000 per patient annually
(in 2013 dollars), placing a financial burden on the U.S.
health care system as well as on individual patients and
their families [10].
Initially several small studies from Europe and
Australia suggested that discontinuing TKIs with regular
monitoring is safe [11–16]. In these studies, 22–61% of
patients with CML in a TKI-induced complete molecular
response maintained this response after discontinuation
of TKIs, and all patients with recurrent CML responded
to reintroduction of TKI therapy. These studies have
varied with regard to sample size (40–124 at the time
LAST was funded), definition of recurrence, and dur-
ation and type of TKI therapy before discontinuation.
Taken together, these results were compelling; however,
CML experts agreed that too little was known about the
variables governing maintenance of molecular response
versus recurrence of leukemia to recommend TKI
discontinuation with monitoring for routine clinical
practice [11, 17, 18]. More recently, several large studies
have completed accrual and additional long term results
are pending [19–22]. Finally, little was known about the
impact of discontinuation on health-related quality of
life, leaving patients and providers without critical
information for deciding whether to discontinue TKI
therapy.
The National Cancer Institute funded the Life After
Stopping TKIs (LAST) study to improve the evidence
for clinical decision making regarding TKI discontinu-
ation with monitoring in CML patients and to shift clin-
ical practice paradigms by reducing uncertainty
regarding TKI discontinuation, and providing critical in-
formation about patient health-related quality of life.
The study has completed the planned accrual, and all
subjects are now being monitored. In this manuscript
we describe the design and rationale for the LAST study.
Methods/design
The co-primary objectives of the LAST study are to de-
termine the proportion of patients with CML who de-
velop molecular recurrence (> 0.1% BCR-ABLIS) after
discontinuing TKIs and to compare the patient-reported
health status of patients before and after stopping TKIs.
The LAST study will also analyze whether there are dis-
ease, patient-related, or treatment-related factors that
predict molecular recurrence, develop a risk scoring sys-
tem to predict the patient’s risk of molecular recurrence
after stopping TKI, assess whether specific time points
are more important for clinical prediction of recurrence
and develop an optimal follow up schedule, and describe
the patient-reported health status of patients who re-
sume TKI therapy after molecular recurrence. Exposure
to TKIs and patient-reported outcomes (PROs) vary be-
tween patients, so patients serve as their own compara-
tors in assessing time to recurrence and health status on
and off TKI therapy. We will compare across patients to
determine predictors of recurrence.
Participants
The target enrollment was 173 patients who met the in-
clusion and exclusion criteria listed in Table 1. Patients
were enrolled at 14 academic medical centers.
Screening and enrollment
A paper log of all potential patients has been kept by
each site, including individuals who decide not to par-
ticipate in or who are found to be ineligible for the
study. Screening is performed for potential study pa-
tients after they have consented to trial participation.
After informed consent, patients are assessed by RQ-
PCR by the Central Molecular Diagnostics Core Labora-
tory at the Fred Hutchinson Cancer Center (Central
Lab) twice, at least 21 days apart, to confirm that the
BCR-ABL is < 0.01% (better than MR4 i.e. > 4 log reduc-
tion). PROs were collected twice during the screening
period to record patients’ baseline, on-therapy health
status. The coordinating center reviewed all documents
to confirm eligibility. Patients were considered to be en-
rolled in the study once the coordinating site has con-
firmed that all screening eligibility criteria had been met;
the TKI was stopped within 7 days of enrollment.
Monitoring
Regular monitoring of BCR-ABL assessments proceeds
as follows: if patient was in the first 6 months of study,
RQ-PCR is performed monthly; if in month 7–24, RQ-
PCR is performed every 2 months; and if in third year,
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RQ-PCR is performed every 3 months. PROs are
assessed monthly for the first 6 months, an additional
assessment at 8 months, and then every 6 months until
study end. For patients who restart TKI therapy, RQ-
PCR is performed approximately every 3 months at the
Central Lab until the patient’s BCR-ABL is < 0.01%
(MR4) two consecutive times or for the duration of the
study, whichever comes first. PROs are assessed in these
patients approximately every 3 months for 1 year and
then approximately every 6 months until study end.
Clinical data is recorded by study coordinators using
OnCore CTMS; PRO data is recorded by patients using
REDCap.
Assessment of BCR-ABL1
Enrolled patients have blood draws for RQ-PCR at the
participating site laboratory, though with permission
they can have certain labs drawn by other laboratories
closer to home. All peripheral blood samples are shipped
fresh to the Central Lab to perform RQ-PCR and digital
testing. The Central Lab uses standard molecular RQ-
PCR monitoring in all patients on the International
Scale (IS). All samples with undetectable BCR-ABL are
also examined using digital PCR, which is a more sensi-
tive nanofluidic PCR system (Fluidigm Corporation,
South San Francisco, CA) with an increased sensitivity
of > 2 log beyond the standard PCR assay [23, 24].
Digital PCR follows the same schedule as RQ-PCR mon-
itoring unless CML recurs, then only RQ-PCR testing is
used thereafter. Digital PCR results will be used for re-
search questions only, with results available to clinicians
only upon conclusion of the study. Thus therapy deci-
sions are made based on RQ-PCR only as per existing
treatment guidelines. During the monitoring phase, if
BCR-ABL is ≥0.01% for the first time, then PCR testing
is repeated monthly for 3 months. If BCR-ABL is ≥0.1%
at any time, patients are instructed to restart TKI ther-
apy. The decision of which TKI to restart is left to the
patient and his/her physician.
Assessment of PROs
PRO assessments are primarily administered electronic-
ally at the clinic/lab, with the site coordinator meeting
with the patient at the time of blood draws and adminis-
tering the assessment through the secure REDCap plat-
form on an iPad. For participants who do not complete
their PRO assessment at the clinic, the local site coord-
inator can 1) email the REDCap link to the participant
to complete the assessment online, 2) access the assess-
ment in REDCap and read the quesitons to the partici-
pant over the telephone, reporting the participant’s
responses directly into REDCap, or 3) give the partici-
pant a paper version of the assessment. The selection of
the PRO domains being measured was based on litera-
ture review, including a recent high-quality qualitative
study on health-related quality of life in 137 CML pat-
ents on TKIs [25]. We used PROMIS measures when
available (Table 2). PROMIS measures are scored on a
standardized scale, where 50 corresponds to the average
in the general U.S. population with a standard deviation
of 10. For additional CML-specific symptoms, we used
the EORTC QLQ-CML Symptom Burden scale, which
includes single items on abdominal pain, dry mouth,
skin problems, headaches, joint pain or swelling, eye
problems, etc. [26] In a longer baseline assessment, we
collected sociodemographic characteristics and monthly
out of pocket expenses for TKIs. In the 3 month assess-
ment we asked additional questions about medications.
Analyses
We will use a 2-tailed significance level of α = 0.05 for
all assessments. Statistical analyses will be conducted
using SAS (SAS Institute, Inc).
Required sample size
We needed sufficient power to detect differences by pa-
tient characteristics in order to predict CML recurrence.
With 173 patients and assuming 5% loss to follow-up
and a 2-tailed significance level of α = 0.05, we will have
Table 1 LAST Study Inclusion and Exclusion Criteria
Inclusion Criteria
Age 18 or older
Willing and able to give informed consent
Diagnosed with CML in chronic phase and have either the b3a2
(e14a2) or b2a2 (e13a2) variants that give rise to the p210 BCR-ABL
protein
Currently taking imatinib, dasatinib, nilotinib or bosutinib
Has been on TKI therapy for at least 3 years
Documented BCR-ABL < 0.01% or undetectable BCR-ABL by RQ-PCR
for at least 2 years according to the patient’s local lab
Documented BCR-ABL < 0.01% or undetectable BCR-ABL by RQ-PCR
at least 3 times prior to screening according to the patient’s local lab
Two (2) Screening PCRs have been completed and both results are <
0.01% (better than MR4, i.e,. > 4 log reduction) by central lab
Has been on any number of TKIs, but has not been resistant to any
TKI (changes made for intolerance are allowed)
Has been compliant with therapy per treating physician
Exclusion Criteria
Prior hematopoietic stem cell transplantation
Poor compliance with taking TKI
Unable to comply with lab appointments schedule and PRO
assessments
Life expectancy less than 36 months
Resistant to previous TKI therapy
Pregnant or lactating women
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90% power to detect a difference of 25% between groups
of equal size (1:1 ratio) in relapse-free survival (RFS) at
18 months.
We also needed sufficient power to detect the smallest
policy-relevant change in health status, which we esti-
mate as an effect size of 0.3, i.e., corresponding to about
1/3 of a standard deviation. We used simulation
methods to conduct a power analysis for a piecewise lin-
ear mixed-effects model in SAS 9.3, assuming 10% miss-
ing data per year to account for dropout and missed
assessments. Relative to the null hypothesis of no time
effect (that is, no difference in PROs over time with TKI
discontinuation and reintroduction), a sample size of
173 patients provides > 90% power to detect a change of
0.3 and > 85% power to detect an effect size of 0.25.
Analysis plan for clinical endpoints
The clinical outcomes to be examined in this pro-
posal include the primary event of CML molecular
recurrence (opposite relapse-free survival [RFS]) and
death in complete remission (DCR). For the univari-
ate analysis the probabilities of RFS will be calculated
using the KaplanMeier- estimator. Probabilities of
molecular recurrence and DCR will be generated
using cumulative incidence estimates to account for
competing risks. Cox proportional hazards model [27]
and Fine and Gray’s subdistribution hazards model
[28] will be used to determine the effect of clinical
characteristics on RFS and CML recurrence after TKI
discontinuation, respectively. The baseline clinical risk
factors that will be considered in regression analyses
include sex, age, type of TKI, time to MR 4.5, dur-
ation in MR 4.5, Sokal Risk score at diagnosis, and
BCR-ABL1 transcript levels measured by digital PCR.
The following analysis plan will be implemented.
First, for the continuous variables, including time to
initial MR 4.5, a martingale residual plot will be ap-
plied to evaluate the potential threshold cut point(s)
for the effect on RFS and the maximum partial likeli-
hood method will be used to identify optimal cut
point(s). Second, univariate probability of RFS, mo-
lecular relapse, and DCR with 95% confidence interval
(CI) will be computed by each clinical risk factor.
Third, a Cox regression model building procedure will
be used to identity significant risk factors associated
with molecular recurrence. The assumption of pro-
portional hazards for each factor in the Cox model
will be tested using time-dependent covariates. When
the test indicates differential effects over time (non-
proportional hazards), models will be constructed
breaking the post-stopping TKI time course into two
periods, using the maximized partial likelihood
method to find the most appropriate breaking time
point. Following this, the proportionality assumptions
will be tested again. Factors that are significant at a
5% level will be kept in the final model. The potential
interactions between all significant risk factors will be
tested. Fourth, based on the final Cox model, a risk
scoring system will be developed to predict the pa-
tient’s risk of molecular recurrence after stopping
TKI. A 3–4 level scoring system will be considered as
appropriate for the data. Our sample is sufficient to
generate the risk scoring system, but future studies
will be necessary for an independent validation of the
system. Fifth, we will assess whether specific time
points are more important for clinical prediction
within this schedule. At each pre-scheduled follow-up
time, we will calculate the recurrence rate and treat-
ment failure rate (recurrence or DCR) with its 95%
CI. We will use the log transfer approach [29] to cal-
culate the CI to force the CI to be within proper
range (0, 1). We will make recommendations for the
optimal follow-up schedule based on the estimated
recurrence rates at each time point.
Table 2 LAST Study Measurement of Patient-Reported
Outcomes
Measure # Items
PROMIS Fatiguea CAT
PROMIS Depressiona CAT
PROMIS Sleep Disturbancea CAT
PROMIS GI Symptoms - Diarrheaa 2
PROMIS GI Symptoms - Nausea 1
PROMIS Physical Function CAT
PROMIS Anxiety CAT
PROMIS Sleep Related Impairment CAT
PROMIS Pain Interference CAT
PROMIS Pain Intensity 1
PROMIS Ability to Participate in Social Roles and Activities CAT
PROMIS Social Isolation CAT
PROMIS Applied Cognition General CAT
PROMIS Interest in Sexual Activity 1
PROMIS Satisfaction with Sex Life 1
PROMIS Alcohol Use 2
PROMIS Global Self-Rated Health 1
PROMIS Global Quality of Life 1
EORTC CML Symptom Burden (includes 1 item on
musculoskeletal paina)
13
Ability to work 2
Ability to pay monthly bills 1
Changes in use of pharmaceuticals 6
Abbreviations: EORTC European Organisation for Research and Treatment of
Cancer; CAT Computerized Adaptive Test; GI Gastrointestinal; PROMIS Patient-
Reported Outcomes Measurement Information System
aHypothesized change of ≥0.3 standardized effect size
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Analysis plan for PROs
The primary objective of the analysis of PRO measures
in this study is to describe what happens to patients’
health status after stopping TKI therapy. A secondary
objective is to describe what happens to the health status
of patients who resume TKI therapy after CML recur-
rence. While we originally proposed a single piecewise
model to answer both questions, this approach includes
the people who did not relapse in the model to answer
the 2nd question. Thus, we pre-specified a revised ap-
proach that uses separate models for each of the two ob-
jectives (outlined in further detail below).
We plan to analyze the components of health-related
quality of life separately (that is, depression separate
from fatigue separate from GI symptoms, etc), since
combining them into a summary score can dilute the ef-
fects of the individual (and not necessarily related) com-
ponents and thus mask true change. However, this
“battery approach” to PRO assessment has the drawback
of resulting in multiple, individual component scores
and 1) raises the possibility of obtaining conflicting re-
sults of the different components and 2) creates a poten-
tial multiple comparisons problem for statistical testing.
Pre-specifying the major expected relationships and cor-
responding statistical comparisons minimizes such po-
tential problems; this is the approach we have taken in
this study.
We hypothesize that, following TKI discontinuation,
fatigue, depression, sleep disturbance, and diarrhea will
improve by at least 3 points each by 6 months post-
discontinuation (corresponding to the standardized ef-
fect size of 0.3 used in our sample size estimation). Since
the initiation of the LAST study, a syndrome of muscu-
loskeletal pain has been reported to occur in some CML
patients after discontinuing TKI therapy [30]. Thus, this
will be an outcome of special interest. Trajectories of the
remaining PROs will also be described, but we have no a
priori hypotheses about how they will change. Likewise,
we hypothesize worsening in fatigue, depression sleep
disturbance, and diarrhea by at least 3 points each by
6 months post-resumption of TKI therapy. In reporting
all results, we will use 95% confidence intervals and
graphical presentations wherever possible to convey the
uncertainty associated with our findings.
Our objectives will be pursued in the context of piece-
wise longitudinal mixed-effects models for each of the
PRO endpoints. This modeling approach offers several
advantages: the likelihood-based estimation means that
all available data from each patient are used; correlations
within patients over time are addressed, and any missing
data can be considered ignorable conditional upon the
observed data [31].
To describe what happens to patients’ health status
after stopping TKI therapy, all patient data while off TKI
therapy will be included. For each PRO domain, growth
curve models will be fit to the data with actual time after
enrollment added to the model as a fixed effect (treated
as a continuous variable drawn from data collection
dates). Because side effects associated with TKIs are ex-
pected to diminish in 1–3 months after discontinuation
of TKIs, the change rate in PROs is not likely to be con-
sistent through the 3-year study period. Although the
growth curves are not expected to be linear, it is reason-
able to approximate the curves to lines over short inter-
vals. Linear approximation will facilitate model
interpretation in a clinical meaningful way. Data visuali-
zations and polynomial models will be used to determine
suitable knots or pieces, that is, how many cut-points to
include and where they should be located in time. New
time variables will be derived to shape the growth curves
after the number and location of knots are determined.
Within-patient dependency will be addressed in the
model via a random intercept and random slopes of each
linear piece.
To describe health status changes after restarting
TKIs, post recurrence, we will use the same methods de-
scribed above with a few modifications. Data will be lim-
ited to the patients who had recurrence and restarted
TKI treatment. A piecewise linear mixed-effects model
will be used to separate each person’s trajectory into two
pieces—one prior to restarting a TKI and one following
the resumption of TKI. The main parameter of interest
will be the estimated change from the new “baseline” at
the assessment just prior to restarting TKI and the
3 month assessment.
For PROMIS CATs, responses were required so there is
no item-level missing. For missing data at the item level
on other measures, we will handle missing values in each
domain using the following approach. If at least 50% of
the items per domain were answered, then we will adjust
the score to ([Raw sum x number of items in the domain]
/ number of items answered). If fewer than 50% of the
items in a domain were answered, we will treat the do-
main as missing. We have chosen the longitudinal mixed
effects model to allow the inclusion of all cases in our ana-
lyses, even those with missing values [32].
Ethics review
The Medical College of Wisconsin (MCW) institutional
review board (IRB) offered to be the IRB of record for
all participating sites, but no sites agreed to cede regula-
tory responsibility. After the MCW IRB granted initial
approval, the multi-site program staff provided regula-
tory documents to the participating institutions includ-
ing initial approval documents, consent forms, site
initiation forms, and amendments. Each participating in-
stitution then sought and obtained local IRB approval
prior to activation of the study at their site. We allowed
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participating institutions to make minor changes to the
consent form to reflect their institutional standards, and
all site-approved consent forms and regulatory docu-
ments were re-reviewed by the multi-site program staff
at MCW. Site IRB approval was forwarded to the MCW
IRB and sites were subsequently activated via a formal
letter.
Data safety monitoring committee
The MCW Cancer Center Data Safety Monitoring Com-
mittee is responsible for monitoring data quality and
subject safety. A 6–8 member DSMC regularly reviews
the protocol-specific data safety monitoring reports to
provide recommendations on trial continuation, suspen-
sion, or termination. As the rate of disease progression
to accelerated phase and/or blast crisis is about 1.2% per
each year, the study will be put on hold if ≥3, 6, 9, 12,
and 15 patients develop disease transformation at end of
years 1, 2, 3, 4, and 5, cumulatively. In the case of a
safety event suspending the study, a prompt cumulative
examination of all data and circumstances of these
events will be conducted to determine whether the study
should be resumed, whether the protocol must be re-
vised, or whether the study will be discontinued
permanently.
Rationale for study design
The LAST study is a non-randomized, prospective,
single-group longitudinal study. Before choosing this de-
sign, we considered a randomized controlled trial (RCT)
and a case-control study. With any study on this topic,
enrollment is expected to be limited to patients who are
both willing to stop TKI therapy and willing to partici-
pate in a research study. With that in mind, we identi-
fied the following concerns with a blinded RCT design:
1) compliance would be problematic—patients in the
trial will know they are being closely monitored for re-
currence, so they will have little incentive to take their
assigned (blinded) pill if they were already inclined to
stop TKI therapy; 2) blinding would be difficult, given
the known side effects associated with TKIs; and 3)
blinding would make it impossible to measure one of
the potential adverse effects of TKI discontinuation that
we are interested in, i.e., anxiety about disease recur-
rence after stopping. Our concerns with using a non-
randomized control group for comparison in a case-
control design are: 1) a comparison of recurrence
between those who do or do not stop TKIs is unneces-
sary since we know that those who continue rarely recur
and a proportion of those who stop will recur; and 2) we
expect that patients who participate in this trial will have
more severe side effects than those who are unwilling to
stop their drug, and comparing these groups would
likely overestimate changes in patient-reported
outcomes. Within the single-group study design, we are
comparing patients to themselves, which we believe
should minimize this bias, but we will report this as a
possible limitation when we interpret our results.
Discussion
LAST is the largest US TKI discontinuation study to
date. Most previous studies have included patients on a
single TKI or required switching from imatinib to sec-
ond generation TKI before discontinuation. LAST is the
only study that allowed any of 4 TKIs. Like previous TKI
discontinuation studies, LAST requires multiple years of
TKI therapy before a discontinuation attempt. We chose
to monitor for recurrence monthly for 6 months, then
every 2 months until 24 months, and then every
3 months until 36 months to contribute to the overall
picture of safety and provide recommendations for an
optimal monitoring schedule. LAST also includes a ro-
bust approach to measurement, including central lab
processing of blood samples during screening, discon-
tinuation, and after restarting; a rigorous approach to as-
sessment of patient-reported outcomes, and use of
digital PCR. Accrual of 173 subjects was completed
within 2 years at 14 participating study sites. No compli-
cations with the molecular monitoring in the Central
Lab nor collection of PROs has occurred. All subjects
are currently being monitored.
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